Integral Health Asset Management
New York, NYfiles as Integral Health Asset Management, LLC
$2.4bn in 89 US stocks at the end of 30 June 2026. The top 10 are 46.5% of the money. It changed about 32.8% of the portfolio this quarter.
Value
$2.4bn
Stocks
89
Top 10 share
46.5%
Turnover
32.8%
What changed this quarter
New
Bought for the first time this quarter.
- Abbott LaboratoriesABT1.5% of the fund
- UnitedHealth GroupUNH1.4% of the fund
- Tenet HealthcareTHC1.3% of the fund
- Spyre TherapeuticsSYRE1.2% of the fund
- Novo Nordisk A SNVO1.2% of the fund
- Travere TherapeuticsTVTX0.9% of the fund
- MedtronicMDT0.6% of the fund
- WatersWAT0.6% of the fund
- Ascendis Pharma A/SASND0.5% of the fund
- iRhythm HoldingsIRTC0.4% of the fund
- Integra Lifesciences HoldingsIART0.4% of the fund
- GE HealthCare TechnologiesGEHC0.4% of the fund
- AbsciABSI0.4% of the fund
- BrukerBRKR0.4% of the fund
- CencoraCOR0.3% of the fund
- Enliven TherapeuticsELVN0.3% of the fund
- BioAge LabsBIOA0.3% of the fund
- Jazz PharmaceuticalsJAZZ0.3% of the fund
- Alkermes plc.ALKS0.2% of the fund
- KardiganKARD0.2% of the fund
- Biontech SEBNTX0.2% of the fund
- Inspire Medical SystemsINSP0.2% of the fund
- Trevi TherapeuticsTRVI0.2% of the fund
- IDEAYA BiosciencesIDYA0.2% of the fund
- Celldex TherapeuticsCLDX0.2% of the fund
Added
Bought more of a stock they already held.
- InsmedINSM7.0% of the fund+7%
- CVS HealthCVS4.7% of the fund+633%
- Edgewise TherapeuticsEWTX3.3% of the fund+25%
- Vera TherapeuticsVERA3.1% of the fund+9%
- Axsome TherapeuticsAXSM3.0% of the fund+757%
- Cardinal HealthCAH2.9% of the fund+11%
- Edwards LifesciencesEW2.3% of the fund+268%
- Quest DiagnosticsDGX1.7% of the fund+233%
- Scholar Rock HoldingSRRK1.7% of the fund+50%
- Boston ScientificBSX1.6% of the fund+64%
- Tango TherapeuticsTNGX1.3% of the fund+122%
- Definium TherapeuticsDFTX1.1% of the fund+38%
- BiogenBIIB0.9% of the fund+67%
- Lantheus HoldingsLNTH0.9% of the fund+52%
- Oric PharmaceuticalsORIC0.8% of the fund+36%
- ErascaERAS0.8% of the fund+43%
- Envista HoldingsNVST0.6% of the fund+71%
- LivaNovaLIVN0.6% of the fund+20%
- Forte Biosciences0.6% of the fund+350%
- Acadia Healthcare CompanyACHC0.5% of the fund+100%
- InventivaIVA0.2% of the fund+280%
- Relmada TherapeuticsRLMD0.1% of the fund+11%
- Sionna TherapeuticsSION0.1% of the fund+50%
Cut
Sold some of their stake.
- Rhythm PharmaceuticalsRYTM2.5% of the fund-8%
- Alignment HealthcareALHC2.0% of the fund-22%
- MerckMRK1.8% of the fund-18%
- BrightSpring Health ServicesBTSG1.6% of the fund-56%
- LifeStance Health GroupLFST1.3% of the fund-30%
- Novartis AGNVS1.3% of the fund-20%
- Regeneron PharmaceuticalsREGN1.0% of the fund-53%
- GlaukosGKOS0.9% of the fund-14%
- AlumisALMS0.8% of the fund-13%
- Elevance HealthELV0.8% of the fund-33%
- CenteneCNC0.8% of the fund-54%
- Arrowhead PharmaceuticalsARWR0.7% of the fund-33%
- Mineralys TherapeuticsMLYS0.5% of the fund-40%
- BiohavenBHVN0.4% of the fund-30%
- RegenxbioRGNX0.4% of the fund-47%
- Cogent BiosciencesCOGT0.3% of the fund-43%
- Sana BiotechnologySANA0.3% of the fund-38%
- Protara TherapeuticsTARA0.2% of the fund-14%
- RezoluteRZLT0.1% of the fund-75%
- Olema PharmaceuticalsOLMA<0.1% of the fund-33%
Sold out
Sold their entire stake.
- AstrazenecaAZN-100%
- Ascendis Pharma A/SASND-100%
- Fresenius Medical Care AGFMS-100%
- Intuitive SurgicalISRG-100%
- Tarsus PharmaceuticalsTARS-100%
- Gilead SciencesGILD-100%
- Elanco Animal HealthELAN-100%
- Dianthus TherapeuticsDNTH-100%
- DexcomDXCM-100%
- Soleno Therapeutics-100%
- Disc MedicineIRON-100%
- Nurix TherapeuticsNRIX-100%
- Cooper CompaniesCOO-100%
- Thermo Fisher ScientificTMO-100%
- Ionis PharmaceuticalsIONS-100%
- CelcuityCELC-100%
- Syndax PharmaceuticalsSNDX-100%
- Viking TherapeuticsVKTX-100%
- Capricor TherapeuticsCAPR-100%
- Iqvia HoldingsIQV-100%
- Protagonist TherapeuticsPTGX-100%
- EvommuneEVMN-100%
- Zimmer Biomet HoldingsZBH-100%
- Immunocore HldgsIMCR-100%
- Maze TherapeuticsMAZE-100%
Holdings
- Forte Biosciences
- Share
- 0.6%
- Value
- $14m
- Shares
- 675,000
+350%
- KardiganKARD
- Share
- 0.2%
- Value
- $5m
- Shares
- 200,000
New
- Biontech SEBNTX
- Share
- 0.2%
- Value
- $5m
- Shares
- 50,000
New
- Mobia MedicalMOBI
- Share
- 0.1%
- Value
- $3m
- Shares
- 250,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Revolution MedicinesRVMD | 11.5% | $281m | 1,500,000 | Held |
| InsmedINSM | 7.0% | $171m | 1,600,000 | +7% |
| CytokineticsCYTK | 5.6% | $136m | 1,600,000 | Held |
| CVS HealthCVS | 4.7% | $114m | 1,100,000 | +633% |
| Edgewise TherapeuticsEWTX | 3.3% | $81m | 2,000,000 | +25% |
| Vera TherapeuticsVERA | 3.1% | $75m | 1,750,000 | +9% |
| Axsome TherapeuticsAXSM | 3.0% | $73m | 300,000 | +757% |
| Cardinal HealthCAH | 2.9% | $71m | 300,000 | +11% |
| Roivant SciencesROIV | 2.9% | $71m | 2,000,000 | Held |
| Rhythm PharmaceuticalsRYTM | 2.5% | $61m | 550,000 | -8% |
| Edwards LifesciencesEW | 2.3% | $57m | 625,000 | +268% |
| Alignment HealthcareALHC | 2.0% | $48m | 2,000,000 | -22% |
| MerckMRK | 1.8% | $45m | 350,000 | -18% |
| Quest DiagnosticsDGX | 1.7% | $42m | 200,000 | +233% |
| uniQureQURE | 1.7% | $41m | 900,000 | Held |
| Scholar Rock HoldingSRRK | 1.7% | $41m | 750,000 | +50% |
| Boston ScientificBSX | 1.6% | $38m | 900,000 | +64% |
| BrightSpring Health ServicesBTSG | 1.6% | $38m | 550,000 | -56% |
| Abbott LaboratoriesABT | 1.5% | $36m | 400,000 | New |
| UnitedHealth GroupUNH | 1.4% | $35m | 85,000 | New |
| LifeStance Health GroupLFST | 1.3% | $32m | 3,000,000 | -30% |
| Novartis AGNVS | 1.3% | $31m | 200,000 | -20% |
| Tango TherapeuticsTNGX | 1.3% | $31m | 1,000,000 | +122% |
| Tenet HealthcareTHC | 1.3% | $31m | 165,000 | New |
| Spyre TherapeuticsSYRE | 1.2% | $29m | 325,000 | New |
| Novo Nordisk A SNVO | 1.2% | $29m | 600,000 | New |
| Definium TherapeuticsDFTX | 1.1% | $26m | 550,000 | +38% |
| Neurocrine BiosciencesNBIX | 1.0% | $25m | 150,000 | Held |
| Regeneron PharmaceuticalsREGN | 1.0% | $25m | 40,000 | -53% |
| BiogenBIIB | 0.9% | $22m | 100,000 | +67% |
| Travere TherapeuticsTVTX | 0.9% | $21m | 375,000 | New |
| Lantheus HoldingsLNTH | 0.9% | $21m | 190,000 | +52% |
| GlaukosGKOS | 0.9% | $21m | 150,000 | -14% |
| Oric PharmaceuticalsORIC | 0.8% | $21m | 1,900,000 | +36% |
| BridgeBio PharmaBBIO | 0.8% | $20m | 275,000 | Held |
| Vertex PharmaceuticalsVRTX | 0.8% | $20m | 40,000 | Held |
| AlumisALMS | 0.8% | $20m | 700,000 | -13% |
| Elevance HealthELV | 0.8% | $19m | 50,000 | -33% |
| CenteneCNC | 0.8% | $19m | 300,000 | -54% |
| ErascaERAS | 0.8% | $18m | 1,000,000 | +43% |
| Eli LillyLLY | 0.7% | $18m | 15,000 | Held |
| Arrowhead PharmaceuticalsARWR | 0.7% | $16m | 200,000 | -33% |
| Envista HoldingsNVST | 0.6% | $16m | 600,000 | +71% |
| MedtronicMDT | 0.6% | $16m | 200,000 | New |
| WatersWAT | 0.6% | $15m | 40,000 | New |
| LivaNovaLIVN | 0.6% | $15m | 180,000 | +20% |
| Forte Biosciences | 0.6% | $14m | 675,000 | +350% |
| Madrigal PharmaceuticalsMDGL | 0.6% | $13m | 25,000 | Held |
| Praxis Precision MedicinesPRAX | 0.5% | $13m | 40,000 | Held |
| Alto NeuroscienceANRO | 0.5% | $13m | 500,000 | Held |
| Mineralys TherapeuticsMLYS | 0.5% | $12m | 450,000 | -40% |
| Xenon PharmaceuticalsXENE | 0.5% | $12m | 200,000 | Held |
| Ascendis Pharma A/SASND | 0.5% | $12m | 45,000 | New |
| Acadia Healthcare CompanyACHC | 0.5% | $12m | 400,000 | +100% |
| iRhythm HoldingsIRTC | 0.4% | $11m | 90,000 | New |
| BiohavenBHVN | 0.4% | $10m | 700,000 | -30% |
| Beam TherapeuticsBEAM | 0.4% | $10m | 300,000 | Held |
| Integra Lifesciences HoldingsIART | 0.4% | $10m | 550,000 | New |
| GE HealthCare TechnologiesGEHC | 0.4% | $10m | 150,000 | New |
| RegenxbioRGNX | 0.4% | $10m | 800,000 | -47% |
| AbsciABSI | 0.4% | $9m | 800,000 | New |
| BrukerBRKR | 0.4% | $9m | 150,000 | New |
| CencoraCOR | 0.3% | $8m | 30,000 | New |
| Cogent BiosciencesCOGT | 0.3% | $8m | 200,000 | -43% |
| Enliven TherapeuticsELVN | 0.3% | $8m | 150,000 | New |
| BioAge LabsBIOA | 0.3% | $7m | 300,000 | New |
| Jazz PharmaceuticalsJAZZ | 0.3% | $7m | 30,000 | New |
| Sana BiotechnologySANA | 0.3% | $7m | 2,000,000 | -38% |
| InventivaIVA | 0.2% | $6m | 1,520,000 | +280% |
| Protara TherapeuticsTARA | 0.2% | $6m | 1,500,000 | -14% |
| Alkermes plc.ALKS | 0.2% | $5m | 100,000 | New |
| LB PharmaceuticalsLBRX | 0.2% | $5m | 150,000 | Held |
| KardiganKARD | 0.2% | $5m | 200,000 | New |
| Biontech SEBNTX | 0.2% | $5m | 50,000 | New |
| Inspire Medical SystemsINSP | 0.2% | $4m | 100,000 | New |
| Trevi TherapeuticsTRVI | 0.2% | $4m | 200,000 | New |
| IDEAYA BiosciencesIDYA | 0.2% | $4m | 100,000 | New |
| Celldex TherapeuticsCLDX | 0.2% | $4m | 100,000 | New |
| SavaraSVRA | 0.2% | $4m | 600,000 | Held |
| Relmada TherapeuticsRLMD | 0.1% | $3m | 500,000 | +11% |
| Mobia MedicalMOBI | 0.1% | $3m | 250,000 | New |
| Sionna TherapeuticsSION | 0.1% | $3m | 75,000 | +50% |
| VeradermicsMANE | 0.1% | $3m | 25,000 | New |
| Inhibikase TherapeuticsIKT | 0.1% | $3m | 1,350,000 | Held |
| RezoluteRZLT | 0.1% | $3m | 500,000 | -75% |
| Denali TherapeuticsDNLI | 0.1% | $3m | 100,000 | New |
| Tenax TherapeuticsTENX | <0.1% | $2m | 167,000 | Held |
| Olema PharmaceuticalsOLMA | <0.1% | $1m | 100,000 | -33% |
| Aura BiosciencesAURA | <0.1% | $1m | 170,000 | New |
Options (3)
- Revolution MedicinesRVMD
- Type
- Put
- Value
- $56m
- Contracts
- 300,000
- Ionis PharmaceuticalsIONS
- Type
- Call
- Value
- $24m
- Contracts
- 300,000
- Novo Nordisk A SNVO
- Type
- Call
- Value
- $14m
- Contracts
- 300,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| Revolution MedicinesRVMD | Put | $56m | 300,000 |
| Ionis PharmaceuticalsIONS | Call | $24m | 300,000 |
| Novo Nordisk A SNVO | Call | $14m | 300,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 127.7% since 30 June 2025.
Where the money is
Health care97.3%
Financial services2.0%
Other0.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.